Niraparib for advanced breast cancer with germline < em > BRCA1 < /em > and < em > BRCA2 < /em > mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study

CONCLUSION: Informative censoring in the control arm prevented accurate assessment of the trial hypothesis, although there was clear evidence of niraparib's activity in this patient population.PMID:34301749 | DOI:10.1158/1078-0432.CCR-21-0310

Source: Clinical Cancer Research - July 24, 2021 Category: Cancer & Oncology Authors: Nicholas C Turner Judith Balma ña Coralie Poncet Theodora Goulioti Konstantinos Tryfonidis Aafke H Honkoop Gabriele Zoppoli Evangelia Razis Oskar Th Johannsson Marco Colleoni Andrew N J Tutt William Audeh Michail Ignatiadis Audrey Mailliez Olivier Tr éd Source Type: research